Literature DB >> 21188471

PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.

Hongbo Chen1, Lin Mei, Lanzhen Zhou, Xiaomeng Shen, Caiping Guo, Yi Zheng, Huijun Zhu, Yongqiang Zhu, Laiqiang Huang.   

Abstract

Glioblastoma is the most frequent and malignant glioma in adults. To develop an effective gene therapy strategy for glioblastoma, we investigated the anti-proliferative effects of phosphatase and tensin homolog (PTEN) restoration and siRNAs specifically targeting PIK3CB and PIK3CA on PTEN-deficient glioblastoma cells in vitro and in subcutaneous xenografts. Restoration of PTEN or knockdown of PIK3CB, but not PIK3CA, in glioblastoma cells markedly down-regulates the phosphorylation level of AKT, inhibits cell proliferation and colony formation, arrests the cell cycle at the G0/G1 stage, and promotes caspase-dependent apoptosis. Combined treatment with PTEN restoration and PIK3CB knockdown shows strong synergy. PTEN restoration or PIK3CB knockdown is also able to efficiently inhibit the growth of human U251 glioblastoma xenografts in nude mice, while tumor growth is entirely suppressed by a combination of the two treatments. In addition, we found that the mRNA levels of inhibitors of apoptosis proteins (IAPs) are reduced in U251 cells by PTEN restoration, suggesting that combined antitumor effects may also be partly attributed to the inhibition of the IAP pathway by PTEN restoration. Collectively, our results demonstrate that PI3 K isoforms play specific roles in tumorigenesis, and that combined treatment of PTEN restoration and PIK3CB siRNA is a promising gene therapy strategy for PTEN-deficient gliomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188471     DOI: 10.1007/s11060-010-0492-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  56 in total

1.  Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.

Authors:  B Wagenknecht; T Glaser; U Naumann; S Kügler; S Isenmann; M Bähr; R Korneluk; P Liston; M Weller
Journal:  Cell Death Differ       Date:  1999-04       Impact factor: 15.828

2.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

3.  Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.

Authors:  Xiu-Mei Cai; Bei-Bei Tao; Li-Ying Wang; Yu-Long Liang; Jia-Wei Jin; Yong Yang; Ya-Li Hu; Xi-Liang Zha
Journal:  Int J Cancer       Date:  2005-12-20       Impact factor: 7.396

4.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

Authors:  D Haas-Kogan; N Shalev; M Wong; G Mills; G Yount; D Stokoe
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

5.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Authors:  Katsutoshi Oda; Jennifer Okada; Luika Timmerman; Pablo Rodriguez-Viciana; David Stokoe; Keiko Shoji; Yuji Taketani; Hiroyuki Kuramoto; Zachary A Knight; Kevan M Shokat; Frank McCormick
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

6.  Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.

Authors:  Venkata Ramesh Dasari; Kiranpreet Kaur; Kiran Kumar Velpula; Meena Gujrati; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

7.  Suppression of PTEN expression by NF-kappa B prevents apoptosis.

Authors:  Krishna Murthi Vasudevan; Sushma Gurumurthy; Vivek M Rangnekar
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 8.  FAK signaling in anaplastic astrocytoma and glioblastoma tumors.

Authors:  Meera Natarajan; Timothy P Hecker; Candece L Gladson
Journal:  Cancer J       Date:  2003 Mar-Apr       Impact factor: 3.360

9.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Authors:  Neil E Torbett; Antonio Luna-Moran; Zachary A Knight; Andrew Houk; Mark Moasser; William Weiss; Kevan M Shokat; David Stokoe
Journal:  Biochem J       Date:  2008-10-01       Impact factor: 3.857

10.  Chromosomal abnormalities in human glioblastomas: gain in chromosome 7p correlating with loss in chromosome 10q.

Authors:  María del Mar Inda; Xing Fan; Jorge Muñoz; Christine Perot; Didier Fauvet; Giselle Danglot; Ana Palacio; Pilar Madero; Idoya Zazpe; Eduardo Portillo; Teresa Tuñón; José María Martínez-Peñuela; Jorge Alfaro; José Eiras; Alain Bernheim; Javier S Castresana
Journal:  Mol Carcinog       Date:  2003-01       Impact factor: 4.784

View more
  25 in total

Review 1.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

2.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 3.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

4.  Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.

Authors:  Xing-Qi Li; Zhi-Gang Ouyang; Sheng-Hua Zhang; Hong Liu; Yue Shang; Yi Li; Yong-Su Zhen
Journal:  J Neurooncol       Date:  2014-05-20       Impact factor: 4.130

5.  A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Authors:  Lillian M Smyth; Kelsey R Monson; Komal Jhaveri; Alexander Drilon; Bob T Li; Wassim Abida; Gopa Iyer; John F Gerecitano; Mrinal Gounder; James J Harding; Martin H Voss; Vicky Makker; Alan L Ho; Pedram Razavi; Alexia Iasonos; Philip Bialer; Mario E Lacouture; Jerrold B Teitcher; Joseph P Erinjeri; Nora Katabi; Matthew G Fury; David M Hyman
Journal:  Invest New Drugs       Date:  2017-03-09       Impact factor: 3.850

6.  Expression of PI3Kp110α and PI3Kp110β in the colorectal conventional adenoma, serrated lesions and adenoma with canceration and their significance.

Authors:  Shuhua Wu; Tangyue Li; Qinghai Mu; Yangyang Li; Xiangqian Gao; Shuang He; Chenbo Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

7.  PTEN Physically Interacts with and Regulates E2F1-mediated Transcription in Lung Cancer.

Authors:  Prerna Malaney; Emily Palumbo; Jonathan Semidey-Hurtado; Jamaal Hardee; Katherine Stanford; Jaymin J Kathiriya; Deepal Patel; Zhi Tian; Diane Allen-Gipson; Vrushank Davé
Journal:  Cell Cycle       Date:  2018-05-31       Impact factor: 4.534

8.  PIK3CB/p110β is a selective survival factor for glioblastoma.

Authors:  Kevin J Pridham; Lamvy Le; Sujuan Guo; Robin T Varghese; Sarah Algino; Yanping Liang; Renee Fajardin; Cara M Rodgers; Gary R Simonds; Deborah F Kelly; Zhi Sheng
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

9.  Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis.

Authors:  Qinglin Li; Yunpeng Bai; L Tiffany Lyle; Guimei Yu; Ovini Amarasinghe; Frederick Nguele Meke; Colin Carlock; Zhong-Yin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-11       Impact factor: 11.205

10.  PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.

Authors:  Paul M Daniel; Gulay Filiz; Daniel V Brown; Michael Christie; Paul M Waring; Yi Zhang; John M Haynes; Colin Pouton; Dustin Flanagan; Elizabeth Vincan; Terrance G Johns; Karen Montgomery; Wayne A Phillips; Theo Mantamadiotis
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.